Baxalta Pays Symphogen $175m Upfront For Immuno-Oncology Program
This article was originally published in Scrip
Executive Summary
As Shire's pursuit of Baxalta approaches the finishing line - if media speculation is to be believed – Baxalta has agreed to pay €160m upfront to Danish antibody company Symphogen for exclusive option rights to an early stage immuno-oncology program.